Current Hepatitis Reports

, Volume 11, Issue 4, pp 256–262

Treatment of Chronic HCV in Special Populations: Thalassemia, Hemophilia, and Hemodialysis Patients

  • Seyed Moayed Alavian
  • Kamran Bagheri Lankarani
  • Ala I. Sharara
Global Perspectives: Middle East (SM Alavian and AI Sharara, Section Editors)


Hepatitis C virus (HCV) infection is a common global health problem. Special patient populations such as those with thalassemia, hemophilia and on hemodialysis are at higher risk for acquiring this infection. Although the incidence of HCV infection has decreased in developed countries, it remains high in developing countries including the Middle East and North Africa region. Management of HCV infection in thalassemia is complicated by severe anemia limiting the use of ribavirin and coexisting iron overload while HCV management in hemophilia patients is more problematic often due to co-infection with HIV. Similarly, chronic kidney disease patients on hemodialysis have special treatment considerations in the management of HCV infection and current guidelines and treatment strategies are largely based on limited data. This review discusses the management the HCV infection in these special populations with emphasis on regional data and considerations.


Hepatitis C Hemophilia Thalassemia Hemodialysis Therapy Epidemiology Middle East 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int. 2011;31 Suppl 2:1–3.PubMedCrossRefGoogle Scholar
  2. 2.
    Brown Jr RS, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl. 2003;9(11):S10–3.PubMedCrossRefGoogle Scholar
  3. 3.
    • Alavian SM, Tabatabaei SH, Mahboobi N. Epidemiology and risk factors of HCV infection among hemodialysis patients in countries of the Eastern Mediterranean Regional Office of WHO (EMRO): a quantitative review of literature. J Public Health (Oxf). 2011;19:191–203. An important regional epidemiologic report on HCV infection in hemodialysis patients.CrossRefGoogle Scholar
  4. 4.
    Alavian SM, Ahmadzad Asl M, Lankarani KB, Shahbabaie MA, Bahrami Ahmadi A, Kabir A. Hepatitis C infection in the general population of Iran: a systematic review. Hepat Mon. 2009;9(3):211–23.Google Scholar
  5. 5.
    Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–41.PubMedGoogle Scholar
  6. 6.
    Alavian SM, Fallahian F. Comparison of seroepidemiology and transmission modes of viral hepatitis C in Iran and Pakistan. Hepat Mon. 2008;8(1):51–9.Google Scholar
  7. 7.
    Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: epidemiology of an emerging infection. Arch Iran Med. 2005;8:84–90.Google Scholar
  8. 8.
    Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, et al. Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma. Hepatology. 2011;53(4):1237–45.PubMedCrossRefGoogle Scholar
  9. 9.
    Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, et al. Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol. 2007;29(4):233–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Alavian SM, Tabatabaei SV, Lankarani KB. Epidemiology of HCV infection among thalassemia patients in eastern mediterranean countries: a quantitative review of literature. Iran Red Cres Med J. 2010;12(4):365–76.Google Scholar
  11. 11.
    Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med. 2006;9:319–23.PubMedGoogle Scholar
  12. 12.
    Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. J Clin Pathol. 1990;43(8):638–40.PubMedCrossRefGoogle Scholar
  13. 13.
    Angelucci E. Antibodies to hepatitis C virus in thalassemia. Haematologica. 1994;79(4):353–5.PubMedGoogle Scholar
  14. 14.
    Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003;37(1):60–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Pimstone NR, Pimstone D, Saicheur T, Powell J, Yu AS. “Wait-and-see”: an alternative approach to managing acute hepatitis C with high-dose interferon-alpha monotherapy. Ann Intern Med. 2004;141(6):W91–2.PubMedGoogle Scholar
  16. 16.
    Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood. 2004;104(1):34–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345(20):1452–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006;130(3):632–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Sharara AI, Aoun E, Koussa S, Inati A, Taher A. Treatment of acute hepatitis C in a child with thalassemia major using weight-based peginterferon alpha-2b. J Gastroenterol Hepatol. 2006;21(7):1221.PubMedCrossRefGoogle Scholar
  20. 20.
    Di Marco V, Lo Iacono O, Capra M, Grutta S, Ciaccio C, Gerardi C, et al. Alpha interferon treatment of chronic hepatitis C in beta-thalassaemia. Gut. 1993;34(2 Suppl):S142–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Donohue SM, Wonke B, Hoffbrand AV, Reittie J, Ganeshaguru K, Scheuer PJ, et al. Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major. Br J Haematol. 1993;83(3):491–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, et al. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol. 2002;97(4):982–7.PubMedGoogle Scholar
  23. 23.
    Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. J Viral Hepat. 2010;17(4):236–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Karimi M, Marvasti VE, Rasekhi A, Kumar PV, Bordbar M, Moshiri A, et al. MRI evaluation of liver iron concentration in patients with beta-thalassemia major. Hepat Mon. 2010;10(2):149–50.PubMedGoogle Scholar
  25. 25.
    Alavian SM, Tabatabaei SV. Treatment outcome of chronic hepatitis C in sickle cell disease and thalassemic patients with interferon and ribavirin. Eur J Gastroenterol Hepatol. 2010;22(1):123–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Alavian SM, Tabatabaei SV, Ayyub M. Outcome of combination antiviral therapy in hepatitis C virus infected patients with sickle cell disease. Saudi Med J. 2009;30(8):1107–8.PubMedGoogle Scholar
  27. 27.
    Burt MJ, Cooksley WG. The influence of iron on chronic hepatitis C. J Gastroenterol Hepatol. 1998;13(3):330–3.PubMedCrossRefGoogle Scholar
  28. 28.
    Van Thiel DH, Friedlander L, Fagiuoli S. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol. 1994;20(3):410–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol. 2002;97(5):1204–10.PubMedGoogle Scholar
  30. 30.
    Fargion S, Fracanzani AL, Sampietro M, Molteni V, Boldorini R, Mattioli M, et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol. 1997;9(5):497–503.PubMedCrossRefGoogle Scholar
  31. 31.
    Taher AT, Musallam KM, Khalife M, Barada K. Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration? Ann Hematol. 2009 Mar 3.Google Scholar
  32. 32.
    Ancel D, Amiot X, Chaslin-Ferbus D, Hagege I, Garioud A, Girot R, et al. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin. Eur J Gastroenterol Hepatol. 2009 Apr 28.Google Scholar
  33. 33.
    Inati A, Taher A, Ghorra S, Koussa S, Taha M, Aoun E, et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol. 2005;130(4):644–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Elizee PK, et al. Low dose ribavirin for treatment of HCV infected thalassemia major patients; new indications for combination therapy. Hepat Mon. 2012;12(6):372–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Artan R, Akcam M, Yilmaz A, Kocacik D. Interferon alpha monotherapy for chronic hepatitis C viral infection in thalassemics and hemodialysis patients. J Chemother. 2005;17(6):651–5.PubMedGoogle Scholar
  36. 36.
    Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr. 1994;125(1):123–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Di Marco V, Lo Iacono O, Almasio P, Ciaccio C, Capra M, Rizzo M, et al. Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C. Blood. 1997;90(6):2207–12.PubMedGoogle Scholar
  38. 38.
    Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematol—Hematol J. 2008;93(8):1247–51.Google Scholar
  39. 39.
    Kountouras D, Koskinas J, Berdoussi H, Vgontza N, Karagiorga M, Lagiandreou A, et al. Efficacy and safety of PEG-IFN alpha-2B treatment for 48 weeks in adult thalassaemic patients with chronic HCV infection. J Hepatol. 2007;46:S190–1.CrossRefGoogle Scholar
  40. 40.
    Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol. 2002;117(3):755–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Mirmomen S, Ebrahimi DN, Malekzadeh R, Zali MR, Alavian SM, Haghpanah B, et al. The efficacy and safety of peginterferon alpha-2a (PEGASYS) monotherapy in the treatment of chronic hepatitis C infected subjects with transfusion dependent thalassemia. Hepat Mon. 2004;4(7):65–70.Google Scholar
  42. 42.
    Mirmomen S, Ghofrani H, Pishbijary HF, Daryani NE, Farahvash MJ, Sharifian RA, et al. Safety and efficacy of interferon alfa for the treatment of chronic hepatitis C infected subjects with transfusion dependent thalassemia in Iran. MJIRI. 2003;17(2):87–95.Google Scholar
  43. 43.
    Pizzarelli G, Di Gregorio F, Romeo MA, Carboni F, Gallisai D, Solinas A, et al. Interferon-alpha therapy in Sicilian and Sardinian polytransfused thalassaemic patients with chronic hepatitis C. BioDrugs. 1999;12(1):55–63.PubMedCrossRefGoogle Scholar
  44. 44.
    Spiliopoulou I, Repanti M, Katinakis S, Karana-Ginopoulou A, Papanastasiou DA. Response to interferon alfa-2b therapy in mutitransfused children with beta-thalassemia and chronic hepatitis C. Eur J Clin Microbiol Infect Dis. 1999;18(10):709–15.PubMedCrossRefGoogle Scholar
  45. 45.
    Syriopoulou V, Daikos GL, Kostaridou SL, Manolaki N, Nakopoulou L, Kattamis A, et al. Sustained response to interferon alpha-2a in thalassemic patients with chronic hepatitis C. A prospective 8-year follow-up study. Haematologica. 2005;90(1):129–31.PubMedGoogle Scholar
  46. 46.
    Telfer PT, Garson JA, Whitby K, Grant PR, Yardumian A, Hoffbrand AV, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol. 1997;98(4):850–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Alter HJ. Post transfusion hepatitis: clinical features, risk and donor testing. Prog Clin Biol Res. 1985;182:47–61.PubMedGoogle Scholar
  48. 48.
    Ghosh K. Challenges of haemophilia care in India: lest we forget. Indian J Med Res. 2009;130(1):87–8.PubMedGoogle Scholar
  49. 49.
    • Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int. 2010;30(8):1173–80. The largest single center study of combination peginterferon and ribavirin therapy in hemophilia patients with chronic HCV infection. PubMedCrossRefGoogle Scholar
  50. 50.
    Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts—blood transfusion. N Engl J Med. 1999;340(6):438–47.PubMedCrossRefGoogle Scholar
  51. 51.
    Samimi-Rad K, Shahbaz B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia. 2007;13(2):156–63.PubMedCrossRefGoogle Scholar
  52. 52.
    Bahakim H, Bakir TM, Arif M, Ramia S. Hepatitis C virus antibodies in high-risk Saudi groups. Vox Sang. 1991;60(3):162–4.PubMedCrossRefGoogle Scholar
  53. 53.
    Fried MW. Management of hepatitis C in the hemophilia patient. Am J Med. 1999;107(6B):85S–9S.PubMedCrossRefGoogle Scholar
  54. 54.
    Brettler DB, Alter HJ, Dienstag JL, Forsberg AD, Levine PH. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood. 1990;76(1):254–6.PubMedGoogle Scholar
  55. 55.
    Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood. 1994;84(4):1020–3.PubMedGoogle Scholar
  56. 56.
    Kumar A, Kulkarni R, Murray DL, Gera R, Scott-Emuakpor AB, Bosma K, et al. Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia. J Med Virol. 1993;41(3):205–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Naumaan M, Zahid H. Markers of viral hepatitis in haemophiliacs. Biomedica. 2006;22(6):3.Google Scholar
  58. 58.
    Makris M, Baglin T, Dusheiko G, Giangrande PL, Lee CA, Ludlam CA, et al. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia. 2001;7(4):339–45.PubMedCrossRefGoogle Scholar
  59. 59.
    Zandieh T, Babaahmadi B, Pourfathollah A, Galedari H, Emam J, Jalalifar MA. Transfusion Transmitted virus (TTV) infection in Thalassemic patients. Iranian J Publ Health. 2005;34(4):5.Google Scholar
  60. 60.
    Rumi MG, De Filippi F, Santagostino E, Colombo M. Hepatitis C in haemophilia: lights and shadows. Haemophilia. 2004;10 Suppl 4:211–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia. 2010;16(1):20–32.PubMedCrossRefGoogle Scholar
  62. 62.
    Alavian SM, Aalaei-Andabili SH. Lack of knowledge about hepatitis C infection rates among in patients with inherited coagulation disorders in countries under the Eastern Mediterranean Region Office of WHO (EMRO): a meta-analysis. Hepat Mon. 2012;12(4):94–102.Google Scholar
  63. 63.
    Keshvari M, Alavian SM, Behnava B, Miri SM, Karimi-Elizee P, Tabatabaei SV, et al. Distribution of hepatitis C virus genotypes in Iranian patients with congenital bleeding disorders. Iran Red Cres Med J. 2010;12(6):608–14.Google Scholar
  64. 64.
    Davarpanah MA, Saberi-Firouzi M, Bagheri Lankarani K, Mehrabani D, Behzad-Behbahani A, Serati A, et al. Hepatitis C virus genotype distribution in Shiraz, Southern Iran. Hepat Mon. 2009;9(2):122–7.Google Scholar
  65. 65.
    Lichterfeld M, Schmeisser N, Qurishi N, Vogel M, Brackmann HH, Spengler U, et al. Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients. J Infect Dis. 2005;50:221–8.Google Scholar
  66. 66.
    Franchini M. Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs? Hematology. 2006;11(3):209–13.PubMedCrossRefGoogle Scholar
  67. 67.
    Wilde JT, Mutimer D, Dolan G, Millar C, Watson HG, Yee TT, et al. UKHCDO guidelines on the management of HCV in patients with hereditary bleeding disorders 2011. Haemophilia. 2011;17(5):e877–83.PubMedGoogle Scholar
  68. 68.
    Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat. 2007;14:371–86.PubMedCrossRefGoogle Scholar
  69. 69.
    Alvarez DF, Latorre JS. Hepatitis C virus and HIV coinfection: clinical management and new strategies. AIDS Read. 2004;14(10 Suppl):S16–21.PubMedGoogle Scholar
  70. 70.
    Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother. 2008 Mar 19.Google Scholar
  71. 71.
    Malekzadeh R, Poustchi H. Fibroscan for assessing liver fibrosis: an acceptable alternative for liver biopsy: fibroscan: an acceptable alternative for liver biopsy. Hepat Mon. 2011;11(3):157–8.PubMedGoogle Scholar
  72. 72.
    Alavian SM. A shield against a monster: hepatitis C in hemodialysis patients. World J Gastroenterol. 2009;15(6):641–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Joukar F, Besharati S, Mirpour H, Mansour-Ghanaei F. Hepatitis C and hepatitis B seroprevalence and associated risk factors in hemodialysis patients in Guilan province, north of Iran: HCV and HBV seroprevalence in hemodialysis patients. Hepat Mon. 2011;11(3):178–81.PubMedGoogle Scholar
  74. 74.
    Alavian SM, Hosseini-Moghaddam SM, Rahnavardi M. Hepatitis C among hemodialysis patients: a review on epidemiologic, diagnostic, and therapeutic features. Hepat Mon. 2007;7(3):153–62.Google Scholar
  75. 75.
    Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S. Hepatitis B and C in dialysis units in Iran: changing the epidemiology. Hemodial Int. 2008;12(3):378–82.PubMedCrossRefGoogle Scholar
  76. 76.
    Alavian SM, Kabir A, Ahmadi AB, Lankarani KB, Shahbabaie MA, Ahmadzad-Asl M. Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodial Int. 2010;14(3):253–62.PubMedCrossRefGoogle Scholar
  77. 77.
    Hosseini Moghaddam SM, Alavian SM, Rahnavardi M. Therapeutic aspects of hepatitis C in hemodialysis patients. Am J Nephrol. 2009;29(2):123–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Rostami Z, Nourbala MH, Alavian SM, Bieraghdar F, Jahani Y, Einollahi B. The impact of hepatitis C virus infection on kidney transplantation outcomes: a systematic review of 18 observational studies: the impact of HCV on renal transplantation. Hepat Mon. 2011;11(4):247–54.PubMedGoogle Scholar
  79. 79.
    •• Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology. 2008;48(5):1690–9. An excellent review on treatment considerations of chronic HVC infection in hemodialysis patients..PubMedCrossRefGoogle Scholar
  80. 80.
    Alavian SM, Tabatabaei SV. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iran J Kidney Dis. 2010;4(3):181–94.PubMedGoogle Scholar
  81. 81.
    Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut. 2008;57(4):525–30.PubMedCrossRefGoogle Scholar
  82. 82.
    • Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection—a pilot study. J Viral Hepat. 2001;8(4):287–92.PubMedCrossRefGoogle Scholar
  83. 83.
    Pawlotsky JM. The results of phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology. 2011;140(3):746–54.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Seyed Moayed Alavian
    • 1
  • Kamran Bagheri Lankarani
    • 2
  • Ala I. Sharara
    • 3
  1. 1.Baqiyatallah Research Center for Gastroenterology and Liver DiseaseBaqiyatallah University of Medical SciencesTehranIran
  2. 2.Health Policy Research CenterShiraz University of Medical SciencesShirazIran
  3. 3.American University of Beirut Medical CenterBeirutLebanon

Personalised recommendations